It was presented during the TCT conference the results of the Cohort A of the PARTNER trial in which the study achieved the primary end points at one year. The conclusing idincates that trascatheter aortic valve implantation (TAVI) is cost effective and improves the quality of patient life for those with severe aortic stenosis who had a transfemoral intervention.  On the hand when transapical procedure was achieved the results were pointing out that is was less economical and quality of life was less performant. The studies included patients with severe aoric stenosis and were randomised to receive either TAVI with a transfemoral or transapical technic or open heart surgery procedure.

The New England Journal of Medicine has publiched the results in 2011.